Loading clinical trials...
Loading clinical trials...
A Phase 1/2, Multicenter Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of HS-10376 Monotherapy in Patients With Advanced Non-small-Cell Lung Cancer
Conditions
Interventions
HS-10376
Locations
1
China
Tianjin Medical University Cancer Institute and Hospital
Tianjin, Tianjin Municipality, China
Start Date
September 30, 2021
Primary Completion Date
October 7, 2024
Completion Date
October 7, 2025
Last Updated
June 28, 2022
NCT05904379
NCT07486648
NCT02932345
Lead Sponsor
Jiangsu Hansoh Pharmaceutical Co., Ltd.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions